MS News that Caught My Eye Last Week: Mavenclad Analysis, Ocrevus and Vaccines, an MS Rehab Technique, a Cattle Toxin and MS
Mavenclad isn’t approved for use in the U.S. but it is approved in Canada, Europe, and other parts of the world. Here’s another positive study of the therapy. Hopefully, it won’t be much longer before Americans can also benefit from it.
An additional analysis of data from the CLARITY study confirmed the long-term benefits of treatment with Mavenclad (cladribine tablets) for patients with highly active relapsing forms of multiple sclerosis (MS).
The post-hoc analysis, “Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study,” was published in the Multiple Sclerosis Journal.
If you’re being treated with Ocrevus, it probably would be a good idea for you to have a chat with your neurologist if you’re planning to get some vaccinations, specifically tetanus, pneumonia, or flu. According to this study, Ocrevus treatment lowers the effectiveness of all three of those vaccines.
Treatment with Ocrevus (ocrelizumab) is linked to a reduced immune response to vaccinations in patients with relapsing multiple sclerosis (MS), according to a Phase 3 trial.
These results were recently presented at the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles, in a presentation titled, “Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis.”
This is a therapy that’s been used to improve limb use in patients who have had a stroke, a traumatic brain injury, or have cerebral palsy. This study suggests it also might be useful for people with MS. The technique involves restraining the stronger arm or leg so that the weaker one is forced to become stronger. The lead researcher calls the results “momentous.”
Constraint-induced movement therapy (CIMT), a rehabilitation technique originally developed for stroke patients, may also be effective in improving limb use in the daily activities of multiple sclerosis (MS) patients, results from a Phase 2 trial show.
Findings were reported in the study, “Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function,” published in the journal Neurorehabilitation and Neural Repair.
Here’s something else that may have an impact on whether someone will develop MS. It’s a toxin found in soil that can seriously sicken sheep, goats, and cattle. As with most early studies, however, more research is needed.
Exposure to epsilon toxin (ETX), which is mainly found in livestock, could be linked to the development of multiple sclerosis (MS), new research suggests.
The study, “Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis,” appeared in the Multiple Sclerosis Journal.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.